AR108202A1 - Reducción de la carga tumoral minimal mediante la administración de antagonistas de ccr1 en combinación con inhibidores de pd-1 o inhibidores pd-l1 - Google Patents
Reducción de la carga tumoral minimal mediante la administración de antagonistas de ccr1 en combinación con inhibidores de pd-1 o inhibidores pd-l1Info
- Publication number
- AR108202A1 AR108202A1 ARP170100898A ARP170100898A AR108202A1 AR 108202 A1 AR108202 A1 AR 108202A1 AR P170100898 A ARP170100898 A AR P170100898A AR P170100898 A ARP170100898 A AR P170100898A AR 108202 A1 AR108202 A1 AR 108202A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitors
- inhibitor
- ccr1
- administration
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
La presente solicitud proporciona métodos para reducir la carga tumoral minimal, el crecimiento tumoral, el avance tumoral y/o la metástasis en un sujeto que padece un cáncer de tumor sólido como por ejemplo el cáncer de mama triple negativo. Los métodos incluyen la administración a un sujeto que lo necesite de una cantidad eficaz terapéuticamente de un inhibidor de PD-L1 o un inhibidor de PD-1 en combinación con un antagonista del receptor de quimiocinas de molécula pequeña que bloquea CCR1. Reivindicación 4: El método de cualquiera de las reivindicaciones 1 a 3, en donde el antagonista del receptor de quimiocina CCR1 tiene la fórmula (1), en donde cada A es N o CH y como mínimo una A es N; R¹ es halógeno; R³ es seleccionado del grupo que consiste en C₁₋₈ alquilo, C₃₋₈ cicloalquilo y C₂₋₈ alquenilo; y R⁸ es C₁₋₈ alquilo; o una sal del mismo aceptable farmacéuticamente. Reivindicación 25: Un equipo para el tratamiento de un sujeto que tiene un cáncer de tumor sólido, dicho equipo comprende una cantidad eficaz terapéuticamente de un antagonista del receptor de quimiocina CCR1 y una cantidad eficaz terapéuticamente de un inhibidor de PD-1 o un inhibidor de PD-L1, con instrucciones para una administración eficaz.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662319689P | 2016-04-07 | 2016-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR108202A1 true AR108202A1 (es) | 2018-07-25 |
Family
ID=59999231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170100898A AR108202A1 (es) | 2016-04-07 | 2017-04-07 | Reducción de la carga tumoral minimal mediante la administración de antagonistas de ccr1 en combinación con inhibidores de pd-1 o inhibidores pd-l1 |
Country Status (20)
Country | Link |
---|---|
US (2) | US10568870B2 (es) |
EP (1) | EP3439653B1 (es) |
JP (2) | JP2019510832A (es) |
KR (1) | KR102370704B1 (es) |
CN (1) | CN109310677A (es) |
AR (1) | AR108202A1 (es) |
AU (1) | AU2017246460B2 (es) |
BR (1) | BR112018070361A2 (es) |
CA (1) | CA3019391A1 (es) |
DK (1) | DK3439653T3 (es) |
ES (1) | ES2864148T3 (es) |
IL (1) | IL261998B2 (es) |
MX (1) | MX2018012132A (es) |
PL (1) | PL3439653T3 (es) |
PT (1) | PT3439653T (es) |
RU (1) | RU2745195C2 (es) |
SG (1) | SG11201808626WA (es) |
TW (1) | TWI808938B (es) |
WO (1) | WO2017176965A1 (es) |
ZA (1) | ZA201806633B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2666730C2 (ru) | 2012-12-07 | 2018-09-12 | Кемосентрикс, Инк. | Диазольные лактамы |
SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
KR20180040138A (ko) | 2015-07-13 | 2018-04-19 | 싸이톰스 테라퓨틱스, 인크. | 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법 |
JP2019510832A (ja) | 2016-04-07 | 2019-04-18 | ケモセントリクス,インコーポレーテッド | Pd−1阻害剤又はpd−l1阻害剤と組み合わせてccr1アンタゴニストを投与することによる腫瘍負荷の低減 |
CN109803651B (zh) | 2016-06-27 | 2022-05-31 | 凯莫森特里克斯股份有限公司 | 免疫调节剂化合物 |
WO2018181425A1 (ja) * | 2017-03-29 | 2018-10-04 | 塩野義製薬株式会社 | 癌治療用医薬組成物 |
BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
IL272258B (en) | 2017-07-28 | 2022-08-01 | Chemocentryx Inc | Immunomodulator compounds |
KR20200056989A (ko) | 2017-08-08 | 2020-05-25 | 케모센트릭스, 인크. | 마크로사이클릭 면역조절제 |
JP2021508696A (ja) * | 2017-12-22 | 2021-03-11 | コーダ−ジェニックス・インコーポレイテッドCoda−Genix, Inc. | がん処置のためのコドン対脱最適化領域を有する組換え型ウイルス及びその使用法 |
US10568874B2 (en) | 2018-02-22 | 2020-02-25 | Chemocentryx, Inc. | Indane-amines as PD-L1 antagonists |
JP7329860B2 (ja) * | 2018-06-15 | 2023-08-21 | ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム | S-エクオールを用いた乳癌の治療及び予防方法 |
US20210236476A1 (en) * | 2018-08-29 | 2021-08-05 | Chemocentryx, Inc. | Methods of treating cancer with small molecule pd-l1 inhibitors |
TW202024638A (zh) * | 2018-09-04 | 2020-07-01 | 美商泰沙羅公司 | 治療癌症之方法 |
WO2020061376A2 (en) | 2018-09-19 | 2020-03-26 | Alpine Immune Sciences, Inc. | Methods and uses of variant cd80 fusion proteins and related constructs |
KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
US20210388091A1 (en) | 2018-11-14 | 2021-12-16 | Regeneron Pharmaceuticals, Inc. | Intralesional administration of pd-1 inhibitors for treating skin cancer |
WO2020176699A1 (en) | 2019-02-28 | 2020-09-03 | Regeneron Pharmaceuticals, Inc. | Administration of pd-1 inhibitors for treating skin cancer |
AU2020231343A1 (en) | 2019-03-06 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer |
WO2021007386A1 (en) | 2019-07-10 | 2021-01-14 | Chemocentryx, Inc. | Indanes as pd-l1 inhibitors |
GB201918692D0 (en) | 2019-12-18 | 2020-01-29 | Cambridge Entpr Ltd | Treatment and prognosis of pancreatic cancer |
TW202207940A (zh) * | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
CN115666724A (zh) | 2020-05-26 | 2023-01-31 | 瑞泽恩制药公司 | 通过施用pd-1抑制剂抗体西米普利单抗来治疗宫颈癌的方法 |
KR20230056761A (ko) | 2020-08-26 | 2023-04-27 | 리제너론 파마슈티칼스 인코포레이티드 | Pd-1 저해제의 투여에 의한 암 치료 방법 |
IL300975A (en) | 2020-09-03 | 2023-04-01 | Regeneron Pharma | Methods for treating cancer pain by administering a PD-1 inhibitor |
CA3198591A1 (en) * | 2020-10-13 | 2022-04-21 | Board Of Regents, The University Of Texas System | Combinatorial immunotherapeutic methods and compositions for pancreatic ductal adenocarcinoma treatment |
WO2022204672A1 (en) | 2021-03-23 | 2022-09-29 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor |
AU2022314735A1 (en) | 2021-07-19 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Combination of checkpoint inhibitors and an oncolytic virus for treating cancer |
WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
WO2023159102A1 (en) | 2022-02-17 | 2023-08-24 | Regeneron Pharmaceuticals, Inc. | Combinations of checkpoint inhibitors and oncolytic virus for treating cancer |
WO2023230220A2 (en) * | 2022-05-25 | 2023-11-30 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19539091A1 (de) | 1995-10-20 | 1997-04-24 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung |
CA2229617A1 (en) | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation |
US6756385B2 (en) | 2000-07-31 | 2004-06-29 | Pfizer Inc. | Imidazole derivatives |
GT200100147A (es) | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
AU2001290258A1 (en) | 2000-09-22 | 2002-04-02 | Nihon Nohyaku Co. Ltd. | N-(4-pyrazolyl)amide derivatives, chemicals for agricultural and horticultural use, and usage of the same |
US20050256130A1 (en) | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
US7842693B2 (en) | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
US7589199B2 (en) | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
PL1618092T3 (pl) | 2003-05-01 | 2011-02-28 | Bristol Myers Squibb Co | Związki amidopirazolowe z podstawnikami arylowymi jako inhibitory kinazy |
EP1883646A1 (en) | 2005-05-19 | 2008-02-06 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
SG10201504801VA (en) | 2005-06-22 | 2015-07-30 | Chemocentryx Inc | Azaindazole compounds and methods of use |
US7777035B2 (en) | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
FR2887450B1 (fr) | 2005-06-23 | 2007-08-24 | Rhodia Chimie Sa | Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques |
JPWO2007026834A1 (ja) | 2005-09-01 | 2009-03-12 | クミアイ化学工業株式会社 | ピラゾール誘導体及び農園芸用除草剤 |
WO2007073432A2 (en) | 2005-10-11 | 2007-06-28 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
US20090252779A1 (en) | 2006-06-22 | 2009-10-08 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
US8022061B2 (en) | 2006-10-10 | 2011-09-20 | Amgen Inc. | N-aryl pyrazole compounds, compositions, and methods for their use |
US20100113776A1 (en) | 2006-12-14 | 2010-05-06 | Taisho Pharmaceutical Co.,Ltd. | Pyrazole derivative |
US7786157B2 (en) | 2007-03-16 | 2010-08-31 | Chemocentryx, Inc. | OXO-imidazolidines as modulators of chemokine receptors |
KR101534661B1 (ko) | 2007-05-22 | 2015-07-09 | 케모센트릭스, 인크. | 3(이미다졸릴)피라졸로〔3,4b〕피리딘 |
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
JP2010530901A (ja) | 2007-06-22 | 2010-09-16 | ハイドラ バイオサイエンシズ インコーポレイテッド | 障害を治療するための方法および組成物 |
KR101571176B1 (ko) | 2007-11-13 | 2015-11-23 | 다이쇼 세이야꾸 가부시끼가이샤 | 페닐피라졸 유도체 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
WO2009137338A1 (en) | 2008-05-06 | 2009-11-12 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
US20120108614A1 (en) | 2008-05-14 | 2012-05-03 | Chong Jayhong A | Compounds and compositions for treating chemical warfare agent-induced injuries |
MX2011002636A (es) | 2008-09-11 | 2011-04-05 | Chemocentryx Inc | 4-amino-3-(imidazoil)-pirazolo[3,4-d]pirimidinas. |
ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
GB0915892D0 (en) | 2009-09-10 | 2009-10-14 | Smithkline Beecham Corp | Compounds |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
US9096642B2 (en) | 2011-06-08 | 2015-08-04 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-pd-l1 항체 및 그의 용도 |
EP2822957A1 (en) | 2012-03-07 | 2015-01-14 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
JP2015512910A (ja) | 2012-03-29 | 2015-04-30 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | ヒトpd1のbcループに由来する免疫調節性環状化合物 |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
EP3556776A1 (en) | 2012-05-31 | 2019-10-23 | F. Hoffmann-La Roche AG | Methods of treating cancer using pd-1 axis binding antagonists and vegf antagonists |
US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
CN104955454B (zh) * | 2012-08-27 | 2018-06-29 | 凯莫森特里克斯股份有限公司 | 趋化因子受体拮抗剂 |
RU2666730C2 (ru) * | 2012-12-07 | 2018-09-12 | Кемосентрикс, Инк. | Диазольные лактамы |
CN104918921B (zh) | 2012-12-21 | 2017-09-22 | 凯莫森特里克斯股份有限公司 | 二唑酰胺 |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
KR20160030936A (ko) * | 2013-07-16 | 2016-03-21 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법 |
JP6586087B2 (ja) | 2013-08-20 | 2019-10-02 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Pd−1アンタゴニストとジナシクリブとの組合せでの癌治療 |
MX2016002544A (es) | 2013-09-04 | 2016-06-17 | Squibb Bristol Myers Co | Compuestos utiles como inmunomoduladores. |
PL3041828T3 (pl) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Technologies Limited | Pochodne 1,3,4-oksadiazolu i 1,3,4-tiadiazolu jako immunomodulatory |
PL3041827T3 (pl) | 2013-09-06 | 2018-09-28 | Aurigene Discovery Tech Limited | Pochodne 1,2,4-oksadiazolu jako immunomodulatory |
CN105813640A (zh) | 2013-09-06 | 2016-07-27 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的环肽类化合物 |
WO2015036927A1 (en) | 2013-09-10 | 2015-03-19 | Aurigene Discovery Technologies Limited | Immunomodulating peptidomimetic derivatives |
WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
EP3149161B1 (en) * | 2014-05-27 | 2021-07-28 | Academia Sinica | Fucosidase from bacteroides and methods using the same |
AU2015289672A1 (en) * | 2014-07-15 | 2017-03-02 | Genentech, Inc. | Compositions for treating cancer using PD-1 axis binding antagonists and MEK inhibitors |
TN2017000084A1 (en) | 2014-09-11 | 2018-07-04 | Bristol Myers Squibb Co | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
SG11201706902SA (en) | 2015-03-10 | 2017-09-28 | Aurigene Discovery Tech Ltd | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
US20180044305A1 (en) | 2015-03-10 | 2018-02-15 | Aurigene Discovery Technologies Limited | 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators |
JP2018513118A (ja) | 2015-03-10 | 2018-05-24 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | 免疫調節剤としての治療性環式化合物 |
US20180044304A1 (en) | 2015-03-10 | 2018-02-15 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators |
AU2016230793B2 (en) | 2015-03-10 | 2021-03-25 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
JP2019510832A (ja) | 2016-04-07 | 2019-04-18 | ケモセントリクス,インコーポレーテッド | Pd−1阻害剤又はpd−l1阻害剤と組み合わせてccr1アンタゴニストを投与することによる腫瘍負荷の低減 |
-
2017
- 2017-04-06 JP JP2019503632A patent/JP2019510832A/ja active Pending
- 2017-04-06 SG SG11201808626WA patent/SG11201808626WA/en unknown
- 2017-04-06 WO PCT/US2017/026290 patent/WO2017176965A1/en active Application Filing
- 2017-04-06 CN CN201780034790.7A patent/CN109310677A/zh active Pending
- 2017-04-06 DK DK17779801.4T patent/DK3439653T3/da active
- 2017-04-06 MX MX2018012132A patent/MX2018012132A/es unknown
- 2017-04-06 PL PL17779801T patent/PL3439653T3/pl unknown
- 2017-04-06 RU RU2018138828A patent/RU2745195C2/ru active
- 2017-04-06 US US15/480,992 patent/US10568870B2/en active Active
- 2017-04-06 AU AU2017246460A patent/AU2017246460B2/en active Active
- 2017-04-06 EP EP17779801.4A patent/EP3439653B1/en active Active
- 2017-04-06 CA CA3019391A patent/CA3019391A1/en active Pending
- 2017-04-06 PT PT177798014T patent/PT3439653T/pt unknown
- 2017-04-06 KR KR1020187032233A patent/KR102370704B1/ko active IP Right Grant
- 2017-04-06 BR BR112018070361A patent/BR112018070361A2/pt active Search and Examination
- 2017-04-06 TW TW106111608A patent/TWI808938B/zh active
- 2017-04-06 IL IL261998A patent/IL261998B2/en unknown
- 2017-04-06 ES ES17779801T patent/ES2864148T3/es active Active
- 2017-04-07 AR ARP170100898A patent/AR108202A1/es unknown
-
2018
- 2018-10-05 ZA ZA2018/06633A patent/ZA201806633B/en unknown
-
2020
- 2020-01-14 US US16/742,139 patent/US11744822B2/en active Active
-
2022
- 2022-06-07 JP JP2022092430A patent/JP2022130424A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3439653B1 (en) | 2021-01-20 |
ZA201806633B (en) | 2021-04-28 |
CN109310677A (zh) | 2019-02-05 |
BR112018070361A2 (pt) | 2019-01-29 |
US20200289472A1 (en) | 2020-09-17 |
US20170290808A1 (en) | 2017-10-12 |
RU2018138828A (ru) | 2020-05-15 |
IL261998B (en) | 2022-11-01 |
ES2864148T3 (es) | 2021-10-13 |
EP3439653A4 (en) | 2019-12-04 |
WO2017176965A1 (en) | 2017-10-12 |
SG11201808626WA (en) | 2018-10-30 |
KR102370704B1 (ko) | 2022-03-03 |
JP2019510832A (ja) | 2019-04-18 |
MX2018012132A (es) | 2019-03-28 |
EP3439653A1 (en) | 2019-02-13 |
PL3439653T3 (pl) | 2021-07-05 |
US10568870B2 (en) | 2020-02-25 |
AU2017246460A1 (en) | 2018-10-25 |
US11744822B2 (en) | 2023-09-05 |
RU2018138828A3 (es) | 2020-08-12 |
DK3439653T3 (da) | 2021-03-29 |
IL261998B2 (en) | 2023-03-01 |
IL261998A (en) | 2018-10-31 |
TW201801724A (zh) | 2018-01-16 |
KR20190020291A (ko) | 2019-02-28 |
TWI808938B (zh) | 2023-07-21 |
CA3019391A1 (en) | 2017-10-12 |
RU2745195C2 (ru) | 2021-03-22 |
JP2022130424A (ja) | 2022-09-06 |
AU2017246460B2 (en) | 2021-04-22 |
PT3439653T (pt) | 2021-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR108202A1 (es) | Reducción de la carga tumoral minimal mediante la administración de antagonistas de ccr1 en combinación con inhibidores de pd-1 o inhibidores pd-l1 | |
CY1123595T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 | |
CL2020000856A1 (es) | Isoquinolinas como inhibidores de hpk1. (divisional solicitud 201902734) | |
CY1121763T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
EA201792214A1 (ru) | Соединения замещенного хиназолина | |
TR201901312T4 (tr) | Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri. | |
EA201690752A1 (ru) | Ингибиторы g12c kras | |
AR101177A1 (es) | Inhibidores de la syk | |
EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
EA201790745A1 (ru) | Трициклические соединения | |
EA201892726A1 (ru) | Дейтерированный палбоциклиб | |
EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k | |
EA201691342A1 (ru) | Пиразолоновые соединения и их применение | |
EA201790870A1 (ru) | Трициклические атропоизомерные соединения | |
DOP2018000238A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
EA201891439A1 (ru) | Трициклические соединения и их композиции в качестве ингибиторов киназ |